3 No-Brainer Dividend Stocks to Buy In July
There's really no such thing as a “no brainer” stock pick. I'd say that some opportunities are more compelling than others.
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?
AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.
A Sweet Spot Between Yield And Growth: The Best Balanced Dividend Growers For 2025
This isn't a buy list. It's a shortlist to help you speed up your research. We've included both U.S. and Canadian names, organized by country. Each company comes with a business summary, plus a bull and bear case to help you assess the fit. Comcast benefits from diversified cash flow through broadband, content creation, and international operations. The business remains cyclical—recessions hit industrial demand, and European expansion poses integration risks. Brand power and wide distribution provide resilience. PepsiCo is expanding its healthier product lines and boosting e-commerce. The shift toward healthier foods poses a threat to legacy products.
AbbVie (ABBV) Laps the Stock Market: Here's Why
AbbVie (ABBV) closed the most recent trading day at $195, moving +2.3% from the previous trading session.
How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?
ABBV leans on Skyrizi and Rinvoq sales strength to offset Humira's decline ahead of its Q2 earnings report.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
2 ETFs To Prepare You For A Potential Recession
I see a 50-60% chance of a recession in the next 12–24 months, so portfolio preparation is essential. I recommend the iShares Gold Trust Micro as a low-cost gold ETF that has outperformed during recent uncertainty and can hedge against downturns. I also like the iShares Core Dividend Growth ETF for its quality holdings, solid dividend growth, and resilience in volatile markets.
Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
AbbVie Stock At $190: Premium Pricing For A Transformation Story
AbbVie (NASDAQ:ABBV) has distinguished itself as one of the top performers in the healthcare sector this year, with its stock rising by 6% while the broader S&P 500 healthcare index fell by 1%. This outperformance is indicative of investor confidence in the pharmaceutical giant's ambitious transformation strategy as it navigates the post-Humira period.
Why AbbVie (ABBV) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Will AbbVie's Acquisition Spree Aid Pipeline Growth?
ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.
ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B
AbbVie's $2.1 billion Capstan deal brings a novel in-vivo CAR-T therapy and tLNP platform to boost its immunology pipeline.
